{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:31:53Z","timestamp":1788517913051,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente M2\/2 founds"],"award-info":[{"award-number":["Ricerca Corrente M2\/2 founds"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocytes ratio, PLR) in predicting the response to<jats:bold>i<\/jats:bold>mmune checkpoint inhibitors (ICI)\u00a0in metastatic melanoma (MM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective study of 272 BRAF wild-type MM patients treated with first line ICI. Bivariable analysis was used to correlate patient\/tumor characteristics with clinical outcomes. Variations between time 1 and time 0 (\u0394) of blood parameters were also calculated and dichotomized using cut-off values assessed by ROC curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, higher neutrophils and NLR negatively correlated with PFS, OS and disease control rate (DCR). Higher PLR was also associated with worse OS. In multivariable analysis, neutrophils (p\u2009=\u20090.003), WBC (p\u2009=\u20090.069) and LDH (p\u2009=\u20090.07) maintained their impact on PFS, while OS was affected by LDH (p\u2009&lt;\u20090.001), neutrophils (p\u2009&lt;\u20090.001) and PLR (p\u2009=\u20090.022), while DCR by LDH (p\u2009=\u20090.03) and neutrophils (p\u2009=\u20090.004). In the longitudinal analysis, PFS negatively correlated with higher \u0394platelets (p\u2009=\u20090.039), \u0394WBC (p\u2009&lt;\u20090.001), and \u0394neutrophils (p\u2009=\u20090.020), and with lower \u0394lymphocytes (p\u2009&lt;\u20090.001). Moreover, higher \u0394NLR and \u0394PLR identified patients with worse PFS, OS and DCR. In the multivariable model, only \u0394NLR influenced PFS (p\u2009=\u20090.004), while OS resulted affected by higher \u0394WBC (p\u2009&lt;\u20090.001) and lower \u0394lymphocytes (p\u2009=\u20090.038). Higher \u0394WBC also affected the DCR (p\u2009=\u20090.003). When clustering patients in 4 categories using basal LDH and \u0394NLR, normal LDH\/lower \u0394NLR showed a higher PFS than high LDH\/higher \u0394NLR (20 vs 5\u00a0months). Moreover, normal LDH\/higher \u0394lymphocytes had a higher OS than high LDH\/lower \u0394lymphocytes (50 vs. 10\u00a0months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Baseline and early variations of blood cells, together with basal LDH, strongly predict the efficacy of ICI in MM. Our findings propose simple, inexpensive biomarkers for a better selection of patient treatments. Prospective multicenter studies are warranted to confirm these data.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-022-03359-x","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:09:36Z","timestamp":1649156976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-0319","authenticated-orcid":false,"given":"Michele","family":"Guida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Quaresmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Pigozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Marco","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Occelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"De Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Monica","family":"Sciacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Stigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"7","key":"3359_CR1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336.","journal-title":"N Engl J Med"},{"issue":"8","key":"3359_CR2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"8","key":"3359_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.","journal-title":"Lancet Oncol"},{"issue":"16","key":"3359_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"3359_CR5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"7","key":"3359_CR6","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.4049\/jimmunol.139.7.2406","volume":"139","author":"A El-Hag","year":"1987","unstructured":"El-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139(7):2406\u201313.","journal-title":"J Immunol"},{"issue":"1","key":"3359_CR7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125(1):127\u201334.","journal-title":"Cancer"},{"key":"3359_CR8","first-page":"18","volume":"18","author":"A Poggi","year":"1988","unstructured":"Poggi A, Vicenzi E, Cioce V, Wasteson A. Platelet contribution to cancer cell growth and migration: the role of platelet growth factors. Haemostasis. 1988;18:18\u201328.","journal-title":"Haemostasis"},{"issue":"1","key":"3359_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/138161211795049804","volume":"17","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47\u201358.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"3359_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125.","journal-title":"J Hematol Oncol"},{"key":"3359_CR11","doi-asserted-by":"crossref","first-page":"107662","DOI":"10.1016\/j.pharmthera.2020.107662","volume":"217","author":"H Zhang","year":"2021","unstructured":"Zhang H, Houghton AM. Good cops turn bad: the contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. Pharmacol Ther. 2021;217:107662.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"3359_CR12","doi-asserted-by":"crossref","first-page":"35378","DOI":"10.1038\/srep35378","volume":"14","author":"W Ma","year":"2016","unstructured":"Ma W, Zhang P, Qi J, Gu L, Zang M, Yao H, et al. Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. Sci Rep. 2016;14(6):35378.","journal-title":"Sci Rep"},{"issue":"9","key":"3359_CR13","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1002\/cam4.2281","volume":"8","author":"W Guo","year":"2019","unstructured":"Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348.","journal-title":"Cancer Med"},{"issue":"1","key":"3359_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/CBM-160614","volume":"17","author":"Y Miao","year":"2016","unstructured":"Miao Y, Yan Q, Li S, Li B, Feng Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark. 2016;17(1):33\u201340.","journal-title":"Cancer Biomark"},{"issue":"11","key":"3359_CR15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/imt-2020-0105","volume":"12","author":"A Kartolo","year":"2020","unstructured":"Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Robinson A, et al. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy. Immunotherapy. 2020;12(11):785\u201398.","journal-title":"Immunotherapy"},{"issue":"1","key":"3359_CR16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cncr.32506","volume":"126","author":"EK Bartlett","year":"2020","unstructured":"Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76\u201385.","journal-title":"Cancer"},{"key":"3359_CR17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2018.05.055","volume":"484","author":"H Zhan","year":"2018","unstructured":"Zhan H, Ma JY, Jian QC. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: a meta-analysis. Clin Chim Acta. 2018;484:136\u201340.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3359_CR18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","volume":"62","author":"AM Di Giacomo","year":"2013","unstructured":"Di Giacomo AM, Calabr\u00f2 L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10\u00a0mg\/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62(6):1021\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3359_CR19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"3359_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.14155","volume":"174","author":"J Zaragoza","year":"2016","unstructured":"Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2016;174(1):146\u201351.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3359_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3359_CR22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaad.2018.03.006","volume":"79","author":"M Garnier","year":"2018","unstructured":"Garnier M, Zaragoza J, B\u00e9n\u00e9ton N, Bens G, Meurisse V, Samimi M, et al. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma. J Am Acad Dermatol. 2018;79(1):165-167.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3359_CR23","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/cancers11101559","volume":"11","author":"M Guida","year":"2019","unstructured":"Guida M, Bartolomeo N, De Risi I, Fucci L, Armenio A, Filannino R, et al. The management of oligoprogression in the landscape of new therapies for metastatic melanoma. Cancers. 2019;11(10):1559.","journal-title":"Cancers"},{"key":"3359_CR24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3389\/fonc.2020.01116","volume":"10","author":"F Zhang","year":"2020","unstructured":"Zhang F, Gorg W. Prognostic value of the platelet-to-lymphocyte ratio in patients with melanoma: a meta-analysis. Front Oncol. 2020;10:1116.","journal-title":"Front Oncol"},{"issue":"3","key":"3359_CR25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5582\/ddt.2020.03043","volume":"14","author":"H Ohashi","year":"2020","unstructured":"Ohashi H, Takeuchi S, Miyagaki T, Kadono T. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma. Drug Discov Ther. 2020;14(3):117\u201321.","journal-title":"Drug Discov Ther"},{"key":"3359_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","volume":"18","author":"MR Cassidy","year":"2017","unstructured":"Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et al. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine. 2017;18:56\u201361.","journal-title":"EBioMedicine"},{"issue":"1","key":"3359_CR27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","volume":"6","author":"AA Lalani","year":"2018","unstructured":"Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3359_CR28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"3359_CR29","unstructured":"The SAS System for Windows. Release 9.4.SAS Inst. Cary, NC, USA, 2011."},{"issue":"9","key":"3359_CR30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351.","journal-title":"Lancet Oncol"},{"key":"3359_CR31","doi-asserted-by":"publisher","first-page":"608406","DOI":"10.1155\/2012\/608406","volume":"2012","author":"V Chew","year":"2012","unstructured":"Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406. https:\/\/doi.org\/10.1155\/2012\/608406.","journal-title":"J Oncol"},{"issue":"34","key":"3359_CR32","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"issue":"6282","key":"3359_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aaf7300","volume":"352","author":"T T\u00fcting","year":"2016","unstructured":"T\u00fcting T, de Visser KE. CANCER. How neutrophils promote metastasis. Science. 2016;352(6282):145\u20136.","journal-title":"Science"},{"issue":"1","key":"3359_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12943-017-0707-7","volume":"16","author":"A Ocana","year":"2017","unstructured":"Ocana A, Nieto-Jim\u00e9nez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16(1):137.","journal-title":"Mol Cancer"},{"issue":"1","key":"3359_CR35","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.1038\/s41598-019-56218-z","volume":"9","author":"R Howard","year":"2019","unstructured":"Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9(1):19673.","journal-title":"Sci Rep"},{"issue":"12","key":"3359_CR36","first-page":"300060520980205","volume":"48","author":"K Liu","year":"2020","unstructured":"Liu K, Jiang G, Fang N, Cai L, Du W, Jia J. Platelet\/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. J Int Med Res. 2020;48(12):300060520980205.","journal-title":"J Int Med Res"},{"issue":"1","key":"3359_CR37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2.","journal-title":"Breast Cancer Res"},{"key":"3359_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2021.03.043","volume":"150","author":"F Corti","year":"2021","unstructured":"Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, et al. The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155\u201367.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3359_CR39","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3359_CR40","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.21037\/apm-20-1389","volume":"9","author":"W Gui","year":"2020","unstructured":"Gui W, Wang X, Luo Y, Wang J. Platelet to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer undergoing palliative treatment. Ann Palliat Med. 2020;9(5):3271\u20137.","journal-title":"Ann Palliat Med"},{"issue":"2","key":"3359_CR41","doi-asserted-by":"crossref","first-page":"e001845","DOI":"10.1136\/jitc-2020-001845","volume":"9","author":"JG Zhou","year":"2021","unstructured":"Zhou JG, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer. 2021;9(2):e001845.","journal-title":"J Immunother Cancer"},{"key":"3359_CR42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176\u201381.","journal-title":"Lung Cancer"},{"issue":"2","key":"3359_CR43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdx059","volume":"29","author":"PF Ferrucci","year":"2018","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2018;29(2):524.","journal-title":"Ann Oncol"},{"issue":"1","key":"3359_CR44","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"3359_CR45","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2019.37.15_suppl.2596","volume":"37","author":"A Russo","year":"2019","unstructured":"Russo A, Franchina T, Ricciardi G, Battaglia A, Schifano S, Schifilliti M, et al. Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15):2596\u20132596.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03359-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T16:52:09Z","timestamp":1675183929000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03359-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3359"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03359-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical, radiological, and laboratory data were collected after obtaining approval by the local Ethics Committee of Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari (prot. nb. 779, July 23rd, 2019) and by the Ethics Committee of each participant Centre, according to the international standards of good clinical practice. All medical data used in this study were irreversibly anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all the patients enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michele Guida: advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre; Pietro Quaglino: speaker fees e advisory boards for BMS, MSD, Pierre-Fabre, Novartis, Roche; Anna Maria Di Giacomo: advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, GSK, Pierre Fabre, Sanofi; Alessandro Marco Minisini: advisory board for Novartis, MSD, Pierre Fabre; Francesco Spagnolo: Honoraria: BMS, Roche, Novartis, MSD, Sanofi, Merck, Sunpharma, Pierre-Fabre. Advisory Board: MSD, Novartis, Sunphama, Pierre Fabre; Marcella Occelli: Speaker role for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche; Paola Queirolo: advisory and consultant role for Roche, BMS, Merck, MSD, Novartis, Pierre Fabre, Sun Pharma, Sanofi; Paolo Antonio Ascierto: consultant\/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD; Vanna Chiaron Sileni: Travel support for medical congress for Bristol Myers-Squibb, lectures fees and Advisory Board for Merck Sharp & Dohme, participation to advisory board for Novartis, Pierre Fabre.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}